Hepatoportal cholangiocarcinoma may be cured clinically after surgery, but because it is a malignant tumor, there is a risk of recurrence and metastasis, so it is difficult to be cured completely. Hepatoportal cholangiocarcinoma refers to malignant tumors originating from the common hepatic duct, the hepatic ductal junction, and the right and left hepatic ducts above the opening of the cystic duct. In the past two decades, with the deeper understanding of the biological behavior of hilar cholangiocarcinoma, the improvement of surgical skills, and the development of imaging, the rate of surgical resection has been increasing, and the efficacy of the treatment of hilar cholangiocarcinoma has been significantly improved. According to some studies, the postoperative recurrence rate of hepatoportal bile duct cancer is still as high as 42%~76%, especially for advanced tumors, high malignancy and small surgical resection scope. There are two main ways of recurrence of hilar cholangiocarcinoma, one is longitudinal regional recurrence, which accounts for about 67%, and the other is distant metastatic recurrence, which accounts for about 33%. This tumor progresses rapidly, the symptoms are more serious after recurrence, and the survival period of patients is shorter, so it is recommended that postoperative patients should have regular recheckups and be given treatment as early as possible according to the results of the recheckups. Patients suspected or diagnosed with hepatoportal cholangiocarcinoma are recommended to go to regular hospitals for comprehensive evaluation of their conditions, follow the doctor’s instructions for treatment, and follow the doctor’s instructions for postoperative checkup to avoid delaying their conditions.